What is the prevalence of the diseases in the USA? Are the diseases specific to ethnicity or
geographical area?

Muscular Dystrophy (MD) is a group of genetic disorders characterized by progressive muscle
weakness and degeneration. It primarily affects the muscles responsible for movement and can
significantly impact a person's quality of life. There are several types of MD, with Duchenne
Muscular Dystrophy (DMD) being the most common and severe form. The prevalence of MD in
the USA is estimated to be around 1 in 5,000 individuals (Duan et al., 2021). While MD can
affect people of all ethnicities and geographical areas, certain forms of the disease may have a
higher prevalence in specific populations due to genetic factors.
Duchenne Muscular Dystrophy, for example, is more commonly found in boys of all ethnicities,
affecting approximately 1 in 5,000 male births. Other forms of MD may have varying
prevalence rates and might be more common in specific ethnic or geographical groups due to
genetic variations. For example, Limb-Girdle Muscular Dystrophy is known to be more
prevalent in individuals of Finnish descent.
What are the routine treatments/outcomes for the disease processes? Is the lifespan
affected by these diseases?

Currently, there is no cure for MD, but several treatments aim to manage symptoms and improve
the patient's quality of life. These treatments include physical therapy, orthopedic interventions,
respiratory support, and medications to manage symptoms like inflammation and pain.
Outcomes for individuals with MD vary depending on the type and severity of the disease (Duan
et al., 2021). While DMD typically has a shorter lifespan, individuals with milder forms of MD
may have a normal lifespan. Advances in care have extended the lifespan and improved the
quality of life for many MD patients.
What research is currently being performed? Where are two clinical trials being
performed?

Cutting-edge research is ongoing in the field of MD. The focus is on developing gene therapies
and treatments to slow down or potentially stop the progression of the disease. One promising

3
approach is exon-skipping therapy, which aims to repair the genetic mutations causing MD.
Additionally, there are clinical trials testing novel treatments, such as CRISPR-based gene
editing and micro-dystrophin gene therapy, to target the root causes of the disease.
Two clinical trials currently being performed include:
1. Clinical Trial 1: A gene therapy trial for DMD is being conducted at the Nationwide
Children's Hospital in Columbus, Ohio (Markati et al., 2022). This trial is evaluating a
treatment that uses viral vectors to deliver a functional dystrophin gene into muscle cells,
potentially improving muscle function and slowing disease progression.
2. Clinical Trial 2: Another clinical trial is ongoing at the University of Florida in
Gainesville. This study is investigating the safety and effectiveness of a gene-editing
technique to correct the dystrophin gene mutation in individuals with DMD (Markati et
al., 2022).

Acute lymphocytic Leukemia Cancer

What is the prevalence of the diseases in the USA? Are the diseases specific to ethnicity or
geographical area?

Acute Lymphocytic Leukemia (ALL) is a type of cancer that affects the white blood cells,
particularly lymphocytes, which play a crucial role in the immune system. It is the most common
childhood cancer, but it can also occur in adults. The prevalence of ALL in the USA is around 1-
2 cases per 100,000 people annually (Haque et al., 2021). ALL can affect individuals of all
ethnicities and geographical areas, but some genetic and environmental factors may increase the
risk.

ALL primarily affects children, with a higher incidence among those of European descent.
However, it can occur in individuals of all ethnic backgrounds. Certain genetic factors and
exposure to environmental toxins may contribute to the development of ALL.

4
What are the routine treatments/outcomes for the disease processes? Is the lifespan
affected by these diseases?

Treatment for ALL typically involves chemotherapy, radiation therapy, and stem cell
transplantation. With modern treatments, the prognosis for children with ALL has greatly
improved, with a high cure rate. In adults, outcomes can vary, and older age is associated with a
less favorable prognosis (Haque et al., 2021). The impact on lifespan depends on various factors,
including the patient's age, subtype of ALL, and response to treatment.
What research is currently bei